Cart
sales@molnova.com
Iohexol
CAS No. 66108-95-0
Iohexol ( Iohexol, Omnipaque, Exypaque, Accudenz, Histodenz, Nycodenz )
Catalog No. M15517 CAS No. 66108-95-0
Iohexol is a contrast agent. Target: Others Iohexol is a contrast agent.
Purity : >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 37 | In Stock |
|
| 500MG | 61 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIohexol
-
NoteResearch use only, not for human use.
-
Brief DescriptionIohexol is a contrast agent. Target: Others Iohexol is a contrast agent.
-
DescriptionIohexol is a contrast agent. Target: Others Iohexol is a contrast agent. The osmolality of iohexol ranges from 322 mOsm/kg-approximately 1.1 times that of blood plasma-to 844 mOsm/kg, almost three times that of blood.
-
SynonymsIohexol, Omnipaque, Exypaque, Accudenz, Histodenz, Nycodenz
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research AreaOther Indications
-
Indication——
Chemical Information
-
CAS Number66108-95-0
-
Formula Weight821.14
-
Molecular FormulaC19H26I3N3O9
-
Purity>98%(HPLC)
-
SolubilitySoluble in DMSO
-
SMILESCC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
-
Chemical NameN1,N3-bis(2,3-dihydroxypropyl)-5-(N-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yin Q, et al. J Am Chem Soc. 2013 Sep 18; 135(37):13620-3.
molnova catalog
related products
-
Nardosinone
Nardosinone has inhibitory effect on Ang II-induced hypertrophy in H9c2 cells, might be mediated by targeting PI3K/Akt and MEK/ERK signaling pathways.
-
N-Benzoyl-(2R,3S)-3-...
(2R, 3S)-N-Benzoyl-3-phenylisoserine is an intermediate in the preparation of potent anticancer drug Paclitaxel used to study the location of the binding sites.
-
C 87
C 87 is a small-molecule TNF-α inhibitor. C 87 directly binds to TNFα, potently inhibits TNF-α-induced cytotoxicity (IC50 = 8.73 μM), and effectively blocks TNF-α-triggered signaling activities.
